Ipratropium bromide hydrate | 66985-17-9

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: Ipratropium bromide hydrate
• 英文别名: [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;bromide;hydrate
• CAS: 66985-17-9；922491-06-3
• 化学式: C20H32BrNO4
• 分子量: 430.4
• InChiKey: KEWHKYJURDBRMN-XFQAGIBXSA-M

物化性质

• 熔点：
  231 °C
• 溶解度：
  H2O：可溶，10mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  -0.97
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  47.5
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

制备方法与用途

应用可作为支气管扩张剂，用于慢性阻塞性肺病（COPD）引起的支气管痉挛的维持治疗。

适应症适用于COPD相关的支气管痉挛的维持治疗，包括慢性支气管炎、肺气肿和哮喘等。

药理学特点为低脂溶性季铵盐，具有极性，口服不易吸收。采用雾化吸入可直接作用于气道发挥作用。本药难以通过跨膜转运进入中枢神经系统，因此吸入给药时全身不良反应较少。

文献信息

• Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
  申请人：Hoelz Hubert

  公开号：US20090092559A1

  公开（公告）日：2009-04-09

  The invention relates to pressurized gas formulations for dosage aerosols, in which a medicament is formulated suspended in TG 227 ea (1,1,1,2,3,3,3-heptafluoropropane) and/or TG 134 a (1,1,1,2-tetrafluoroethane) as a propellant, and to their use for producing a medicament. The aerosol is preferably an inhalation aerosol.

  本发明涉及压力气体配方用于剂量气雾剂，其中药物配制悬浮于TG 227 ea（1,1,1,2,3,3,3-七氟丙烷）和/或TG 134a（1,1,1,2-四氟乙烷）作为推进剂，并用于制备药物。气雾剂最好是吸入气雾剂。
• FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION
  申请人：Kindeva Drug Delivery L.P.

  公开号：EP3860580A2

  公开（公告）日：2021-08-11
• Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant
  申请人：Schmelzer Christel

  公开号：US20060002863A1

  公开（公告）日：2006-01-05

  Disclosed are propellant gas formulations containing at least one suspended active substance which contains chemically bound water, water and the propellant TG 227 or TG 134 a.
• COMPOSITIONS AND METHODS FOR HYPERHIDROSIS
  申请人：Koleng John J.

  公开号：US20100137357A1

  公开（公告）日：2010-06-03

  The present disclosure relates, according to some embodiments, to compositions, systems, and methods for ameliorating, preventing, and/or treating (collectively “treating”) hyperhidrosis and/or excessive perspiration (collectively “hyperhidrosis”). For example, a method for treating hyperhidrosis may comprise administering (e.g., topically administering) a composition comprising an anticholinergic compound (e.g., an ipratropium compound) to a mammal. A composition (e.g., a topical composition) for treating hyperhidrosis may comprise an anticholinergic compound (e.g., an ipratropium compound) and a vehicle (e.g., a physiologically acceptable vehicle). In some embodiments, administering a composition comprising an anticholinergic compound may comprise contacting the subject with a medicated article comprising the composition.
• TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS
  申请人：UTI LIMITED PARTNERSHIP

  公开号：US20190262353A1

  公开（公告）日：2019-08-29

  In one aspect, there is provided a method of treating, prophylaxis, or amelioration of a neurological disease by administering to a subject in need thereof one or more compounds described herein. In a specific example, the neurological disease is multiple sclerosis (also referred to as “MS”).